Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$58.85 USD
+0.06 (0.10%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $58.81 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EXAS 58.85 +0.06(0.10%)
Will EXAS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXAS
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
Other News for EXAS
Exact Sciences Announces Board Member Retirement
Artisan Mid Cap Fund Q1 2024 Commentary
Baron Health Care Fund Q1 2024 Shareholder Letter
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Exact Sciences CFO's resume 'impressive,' says William Blair